{"name":"Marcus Maurer","slug":"marcus-maurer","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Rupatadin","genericName":"Rupatadin","slug":"rupatadin","indication":"Allergic rhinitis","status":"phase_2"}]}],"pipeline":[{"name":"Rupatadin","genericName":"Rupatadin","slug":"rupatadin","phase":"phase_2","mechanism":"Platelet-activating factor receptor, Histamine H1 receptor","indications":["Allergic rhinitis","Urticaria"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPcXJmUVBOa2RHMDZTYzN0WGVEMFVLLUctSWlIUm5lalhtMDYyZHZMdUtMMkozMWhINGZrZ1hpSXY5WkdXMWZaWHAxUFFobkpZVXZtVkdzb1dRWkpxMGhRYUZUY1c3b2l3ZVdGYlhfNWdpRVo4TWFFWW5HOFZncTVyR21FQzg1ZUdaUFlaNXpRQTkybzBCQUlINUZfaHpTdmlEb1E?oc=5","date":"2025-03-07","type":"pipeline","source":"Medscape","summary":"Remibrutinib Yields Rapid, Sustained Relief in Chronic Spontaneous Urticaria - Medscape","headline":"Remibrutinib Yields Rapid, Sustained Relief in Chronic Spontaneous Urticaria","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwJBVV95cUxPRlpBWGIxQzV1R2Y4RjRVYkJlUFA2WTl5eFRENDc1eGViV0plbmFSaC1waFdXNGRrMDBJRkNnOWNZYUREQ1RqbXQzQV84YVVHN21SbEQxT2h1Z1ppS1RjLWpvNG44eHROY3ZtanAtVkVvc3JNdzVMUnFPVDhQTjc0OXRmQy1FOWRxQk1rXzNJR200OERJNTdtZHB0MnNqLS1qQ3JzWWNsVGJWZnozZ0F4d2xhRVVlUXZUb2ZLVkRLSWIta3NfOUwyOENBT0VtTGltU3BJQUdIUkJMd0NkOHVZcEhRTWIyOU9GdmNHVEVQUTlIbllPa2FOZ2JsLV92R1N0a2REcWFyblhmYkxnd0JBRXNhTF9uLTNiV0p0LXowdlZIUDgxTEtF?oc=5","date":"2024-05-06","type":"pipeline","source":"PR Newswire","summary":"ALLEGRIA THERAPEUTICS ANNOUNCES SEED FINANCING TO ADVANCE PIPELINE OF NOVEL AND SELECTIVE THERAPEUTIC APPROACHES FOR MAST CELL-MEDIATED DISEASES - PR Newswire","headline":"ALLEGRIA THERAPEUTICS ANNOUNCES SEED FINANCING TO ADVANCE PIPELINE OF NOVEL AND SELECTIVE THERAPEUTIC APPROACHES FOR MAS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxPQVhTMmh6TUdDTWZvWEdPa3hKS3ZndDc3MW44MnYwRV96LTZ2NldrTzFPYXNRS2ZZUDFXazR5eVpyX084T1YzQnlZR2MwWkkzVmJzTnU4SGlwSlAyLWx0ckJrMkNnS3dVMmxITHhxY1phX3hpMEZST2ZfTndGMDNleU1ydzhMaXJ0MTBqcjhlTWdqc1c4MHVVWlE1TDJETVFLTU1sTnhpblktVndsd2t2eVVVX1lZci1mQ3diMEluRVJqRnNQYmt0ejVFTmE3NnhMNmxBcC1B?oc=5","date":"2024-03-25","type":"pipeline","source":"Healio","summary":"Quality of life improves with dupilumab for patients with chronic spontaneous urticaria - Healio","headline":"Quality of life improves with dupilumab for patients with chronic spontaneous urticaria","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOemdXd2xhQnZ5OGxtOG1td1hhdzYxelBQclpFODhqd1MyZHhrTHNHc09LSV9veEE5UEsyRE1KSjZCaDNoOHZ0clZydG40S1MyOERhQ0l0Znd4SnM0QXN4U1pUVExxU0IxcWFKV29ieXY0blM0TmxyTzRncUF3ZWJodUI2VnFoVnA1aVFvS0RueWw1U0RqZ0FFZThlUkdxX2RmNzdYTDE1WnlwT1lZREpueTJzaDk3SWxzQ2c?oc=5","date":"2024-03-25","type":"regulatory","source":"Fierce Biotech","summary":"Astria's pipeline star reduces hereditary angioedema attacks in early phase 1b/2 data - Fierce Biotech","headline":"Astria's pipeline star reduces hereditary angioedema attacks in early phase 1b/2 data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE5OVGt0VGZrVTI5RkQ1WHk0eEx1NkxuN3hIME4yR0podS0wTUgzWm50S3NoMGxvU1hEMTh3SW5WdEdkV3pkVEI3M29qZl9DVWN0SjRpVDNYak5ITmZrM1JxNVE1eWs0ZzFZSkE?oc=5","date":"2024-03-05","type":"pipeline","source":"Wiley Online Library","summary":"Journal of the European Academy of Dermatology and Venereology - Wiley Online Library","headline":"Journal of the European Academy of Dermatology and Venereology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE8tRUVRU0JxZmFneWkwMHhZOG4wN1BXS0p4RWtFa3VnQzRZVlBfTURudzUzQlkzanlIYUlYbVpkS1NDazdhOFpIMm54eFFRd3MzSEpOUzBmUGdNTUVpMGV1OFBBSGFzVXc?oc=5","date":"2022-02-27","type":"pipeline","source":"MedPage Today","summary":"Dupilumab May Help in Tough-to-Treat Chronic Spontaneous Urticaria - MedPage Today","headline":"Dupilumab May Help in Tough-to-Treat Chronic Spontaneous Urticaria","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxQVmtQQ3FfbWdyWGNONGFNbGFyOVJYOXItWXIzbFpUOUJwNEo3MnNlVmw3a3dlZTg5LTk0WU81U3dwdmRuSDFpZllZelBBUVJPS3p0U1FCWFBEaUJqNHdvZTRWT3k0Mk10XzBYRjBNWk04aEswYVFZdS1waGM1dTdQWVBhWU40Rk5Fc3hnNlI4d0JSYnBRZE1yM0ZHVElBaThMcDljdWswdzlJYXlSc2pMejV5dDJEMk5jU1B4SHJRZkFjcGlDVWlwM3lxa29fb3RQQUdmdXFB?oc=5","date":"2021-11-11","type":"pipeline","source":"European Medical Journal","summary":"The Benefits of Achieving Complete Control in Patients with Chronic Spontaneous Urticaria - European Medical Journal","headline":"The Benefits of Achieving Complete Control in Patients with Chronic Spontaneous Urticaria","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE5PYVItb2h3WXowdXVPNWJ0TTlEMVZwN0h1OWNSci1vX3h2X3BwYVd1QWxDRDkzc1BLOUk3ZEdoSkN5TTVSNnQxdDRiMy0teTZxeE9LcTNsVGN2SWV1dGppdmhLRk9GTzBveVlPUw?oc=5","date":"2021-08-26","type":"regulatory","source":"Wiley Online Library","summary":"Automatic screening of self-evaluation apps for urticaria and angioedema shows a high unmet need - Wiley Online Library","headline":"Automatic screening of self-evaluation apps for urticaria and angioedema shows a high unmet need","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE5MZV8zcEpyTUJWMURBSU5OUGY5QTBUSEJobWhjOTROTmZJR3pxYlR3Yi1NcWt2djVTSDlGR2NINXJDazBOa1BoekUyM0dNeWxmWEJiX1N4dUdhOXprQi1zQVN5TVJ6Rl9QNldDeXA0djZQZW9vUDR4akFTekFFdw?oc=5","date":"2021-07-09","type":"pipeline","source":"BioPharma Dive","summary":"Celldex pins its hopes for a comeback on skin disease drug - BioPharma Dive","headline":"Celldex pins its hopes for a comeback on skin disease drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE9lQTRmMnNvM0RaQ1ZXT2RSeThBblhUTHc2RnloZUdNUllIRmNhOWZKTlhCSnpUZ1dvWEY4dHR4Q3RhZnAzNXd3dXM1d3locWw0Y2lScjJxR0hGdGNNX2pJRg?oc=5","date":"2019-10-02","type":"pipeline","source":"NEJM","summary":"Ligelizumab for Chronic Spontaneous Urticaria - NEJM","headline":"Ligelizumab for Chronic Spontaneous Urticaria","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPMnFQVlB3Tkg0ODROQ09VaExlQkI3Q3FWSlBKcU9lOFh1cWFFd3ZnTElEc2dmaFg4X09RUURnV2dsdnl1cWJQd0JmNXNWbThOLV96cnNNQ0R2cDF5WFNETFVrMWI5SGlHWXo3OC1leEdOTXloT3BpSndvcHdQd3EyRV9qeEhRT2dtdk5UdW9pYlhremxmWWFaYWJfOW5xV3VpVHNkMTlxS2l0a3lkOWwtbWlqVHlSLXkwRXlSdmtuQjBKdUNBNXc?oc=5","date":"2018-03-09","type":"pipeline","source":"Hospital Pharmacy Europe","summary":"Omalizumab recommended in new global chronic urticaria guideline - Hospital Pharmacy Europe","headline":"Omalizumab recommended in new global chronic urticaria guideline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE4tYV9RUWxISUUtY3hsYnBnS3VEVDJGeFVzLTg1QWVEaVFJS1Q3YnJfakhKVnlxbnNmS19MSXZOUWRERkw4dWU2UDY2SUdWS1M5RzBNREJPM1BoVzBKeE9BNA?oc=5","date":"2013-02-24","type":"pipeline","source":"NEJM","summary":"Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria - NEJM","headline":"Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}